GlassScriptPhysician profile
Samuel P Pike
NPI 1104832310
$570.09
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $203 · 2021: $14.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $71.22 | 2019-2020 | |
| Glaxosmithkline, LLC. | $66.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $58.53 | 2019-2020 | |
| Amgen INC. | $49.83 | 2019-2020 | |
| Novo Nordisk INC | $44.64 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $36.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $35.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.70 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.87 | 2019 | |
| Allergan, INC. | $31.18 | 2020 | |
| Astellas Pharma US INC | $29.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.20 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.44 | 2020 | |
| Merck Sharp & Dohme LLC | $12.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.90 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Pike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.